On April 4, 2025, a select group of international experts in dermatologic oncology participated in a live workshop to discuss treatment options in high-risk or locally advanced/metastatic melanoma and non-melanoma skin cancers in an evolving treatment landscape. Caroline Robert, MD, PhD, led the discussion, obtaining perspectives on the available evidence about immunotherapy options and insights into treatment preferences for high-risk cutaneous squamous cell carcinoma that is either locally advanced (laCSCC) or metastatic (mCSCC) and advanced/metastatic cutaneous melanoma.
Read More
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025On February 13, 2025, a select group of experts in chronic lymphocytic leukemia (CLL) participated in a virtual workshop to discuss the evolving treatment landscape of CLL and discussed subjects ranging from treatment of newly diagnosed patients to therapies for those relapsed/refractory (R/R) disease. Moderated by Alexey V. Danilov, MD, PhD, the discussion covered insights into emerging treatment approaches, novel therapeutic strategies, and sequencing of available therapies to optimize patient outcomes. This article was supported in part by Eli Lilly. Content independently developed and published by OncLive.
Read More
Updates in the Diagnosis and Management of HER2-Mutant NSCLC
February 27th 2025On January 30, 2025, a group of thoracic oncologists gathered for an in-person workshop to discuss advances in diagnosing and treating non–small cell lung cancer (NSCLC) related to an HER2 mutation. The session was moderated by Joshua Sabari, MD; and Benjamin Levy, MD. As they focused on HER2 biomarker testing, treatment sequencing, and emerging therapies (including antibody-drug conjugates [ADCs] and TKIs), the faculty reviewed clinical trial data, shared real-world experiences, and debated evolving treatment strategies.
Read More
Molecular Testing Approaches for RAI-Refractory DTC
January 7th 2022Marcia Brose, MD, PhD, FASCO, and Maria E. Cabanillas, MD, compare the use of molecular testing for radioactive iodine-refractory differentiated thyroid cancer at their institutions and highlight predictive and prognostic biomarkers.
Read More
Approaches to Initiating Therapy for a Patient With CLL and Worsening Symptoms
December 6th 2021Oncology hematology health care professionals from Memorial Sloan Kettering Cancer Center discuss how to manage a 67-year-old woman with chronic lymphocytic leukemia who develops progressive fatigue and night sweats.
Read More